New hope for women with resistant ovarian cancer: drug combo shows promise
NCT ID NCT07314619
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, in 30 women with platinum-resistant recurrent ovarian cancer. The goal is to see if the combo can shrink tumors and delay cancer growth better than current options. Participants must have had 1 to 3 prior treatments and have platinum-resistant disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.